Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Emily Hayes
AstraZeneca's EXSCEL study could have created confidence in a GLP-1 class-wide outcomes benefit, but instead it has raised questions about whether differences in trial results boil down to trial design.
La Jolla's LJPC-501 meets primary blood pressure endpoint in the Phase III ATHOS-3 vasodilatory shock trial, but data suggest benefits may not translate into clinically meaningful improvements.
The immuno-oncology highlight of the upcoming American Society of Clinical Oncology annual meeting will be clinical data for Incyte's epacadostat with Merck's Keytruda as well as data with Bristol's Opdivo.
IDO has emerged at the lead suitor among new cancer immunotherapy targets to partner with PD-1/L1 inhibitors; the early data help show why big pharmas are so much on board.
Study done in China may prompt a change the standard of care in the US to include earlier testing for EGFR mutations after surgery, but is unlikely to change treatment protocols until overall survival data are available.
US payers may increasingly look to leverage the competition among the novel oral anticoagulants by contracting for preferred coverage with two of the leading drugs in the field, rather than all three.